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AbstrAct
KRAS is mutated in about 20-25% of all human cancers and especially in 
pancreatic, lung and colorectal tumors. Oncogenic KRAS stimulates several pro-
survival pathways, but it also triggers the trans-activation of pro-apoptotic genes. 
In our work, we show that G13D mutations of KRAS activate the MAPK pathway, 
and ERK2, but not ERK1, up-regulates Noxa basal levels. Accordingly, premalignant 
epithelial cells are sensitized to various cytotoxic compounds in a Noxa-dependent 
manner. In contrast to these findings, colorectal cancer cell sensitivity to treatment 
is independent of KRAS status and Noxa levels are not up-regulated in the presence 
of mutated KRAS despite the fact that ERK2 still promotes Noxa expression. We 
therefore speculated that other survival pathways are counteracting the pro-apoptotic 
effect of mutated KRAS and found that the inhibition of AKT restores sensitivity to 
treatment, especially in presence of oncogenic KRAS. In conclusion, our work suggests 
that the pharmacological inhibition of the pathways triggered by mutated KRAS could 
also switch off its oncogene-activated pro-apoptotic stimulation. On the contrary, the 
combination of chemotherapy to inhibitors of specific pro-survival pathways, such as 
the one controlled by AKT, could enhance treatment efficacy by exploiting the pro-
death stimulation derived by oncogene activation.
IntroductIon
KRAS is a 21 KDa protein involved in cell signal 
transduction belonging to the RAS subfamily, which 
comprises several other small GTPases endowed with 
GTP-hydrolyzing activity. In unstimulated conditions, 
GTPases are bound to GDP and display low activity, 
unable to trigger the down-stream signaling processes. 
RAS proteins require GTP to be activated and undergo 
rapid cycles of activation and inactivation crucial for 
physiological signaling [1]. Because these cascades 
stimulate cell growth and division, aberrant RAS signaling 
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can also lead to cancer. The 3 human RAS genes (HRAS, 
KRAS, and NRAS) are among the most prevalent drivers 
of human cancer, with KRAS being mutated in 20-25% 
of all human tumors and up to 90% in certain cancer 
types, e.g. pancreatic cancer [2]. In these settings, KRAS 
activates several down-stream effectors leading to the 
stimulation of the RAF/mitogen-activated protein kinase 
kinase/extracellular signal-regulated kinase (RAF/MEK/
ERK) and phosphatidylinositol-3-kinase (PI3K) pathways.
Colorectal cancer (CRC), one of the most 
widespread cancer types, displays in 40% of cases 
KRAS activating mutations, primarily involving codon 
12 or 13. Several drug combinations are currently used 
for CRC treatment, including oxaliplatin, 5-FU and the 
camptothecin (CPT) analogue irinotecan [3]. Moreover, 
the epidermal growth factor receptor (EGFR)-blocking 
antibodies cetuximab and panitumumab are approved 
for treatment of metastatic CRC in combination 
with chemotherapy and as maintenance therapy in 
chemorefractory tumors. Receptor tyrosine kinases such as 
EGFR, through the activation of the downstream GTPases, 
regulate MAPK and PI3K pathways. Importantly, 
mutations or amplification of KRAS is often associated 
to unresponsiveness and acquired resistance to cetuximab 
[4]. 
Even though oncogenic KRAS is often associated 
with poorer prognosis, its mutations have also been 
considered for targeted therapy taking advantage of 
combinations that produce a synthetic lethal effect [5, 
6]. In fact, the presence of constitutively active KRAS 
sensitizes cancer cells to MEK and BCL-XL [7] or RAF 
[8] inhibition, TRAIL [9], 5-FU and oxaliplatin [10]. 
Nonetheless, KRAS activation is usually associated with 
reduced proneness to apoptosis and increased resistance 
to chemotherapy owing to the activation of pro-survival 
pathways [11-13] and resulting in the up-regulation of 
anti-apoptotic factors such as the members of the inhibitor 
of apoptosis proteins (IAP) family [14, 15].
IAPs are characterized by the presence of a 
conserved baculoviral IAP repeat (BIR) domain [16] 
important for protein-protein interactions. Despite the 8 
members of the IAP family had initially been considered 
essentially apoptosis negative regulators, only X-linked 
IAP (XIAP) is known to physically interact with caspases 
and prevent their activity [17]. Later studies have shown 
that IAPs regulate cell life aspects other than apoptosis. 
Cellular IAP1 (cIAP1) and cIAP2, for example, modulate 
the signaling of pro-survival pathways, such as the ones 
regulated by NF-kB transcription factors and MAPKs 
[16]. Interestingly, IAPs are often deregulated in cancer 
cells and associated to unfavorable prognosis [18]. An 
opportunity to target IAPs, and especially cIAP1, cIAP2 
and XIAP, both for therapeutic purposes and as tools in 
pre-clinic research is represented by second mitochondria-
derived activator of caspases (SMAC) mimetic (SM) small 
compounds [19]. SMs were designed to mimic the activity 
of SMAC [20], a natural antagonist of XIAP, which, by 
interacting with its BIR domains, displaces caspases 
and promotes their activity with consequent apoptosis 
induction. SMs also target cIAP1 and cIAP2, causing 
their degradation [21, 22], modulating several pathways 
and overcoming cancer cell resistance to therapy [23] 
and especially to tumor necrosis factor-related apoptosis 
inducing ligand (TRAIL) [20, 24].
Here we report that SM83, a SM recently described 
by us [25, 26], greatly enhances the cytotoxic activity of 
the topoisomerase I inhibitor CPT in premalignant models 
in which KRAS G13D is endogenously or ectopically 
expressed in human epithelial cells. The increased 
sensitivity of oncogenic KRAS-expressing cells stems 
at least in part from the basal up-regulation of the pro-
apoptotic protein Noxa, which is stimulated in an ERK2-
dependent manner. In clear contrast to the premalignant 
models, a panel of CRC lines with knock-in (KI) and 
knock-out (KO) mutations of KRAS G13D showed that 
the sensitivity to treatment is independent of KRAS status. 
Accordingly, Noxa levels are unaffected by oncogenic 
KRAS expression and other pathways, such as the ones 
controlled by PI3K/AKT, protect cancer cells from the 
potentially pro-apoptotic stimulus of mutated KRAS.
results
the combination of sMs and cPt selectively kills 
premalignant epithelial cells bearing oncogenic 
KRAS
As SMs are rarely effective in monotherapy, but 
sensitize cancer cells to other compounds, we searched 
for drugs whose cytotoxicity can be efficiently enhanced 
by SM83 using a high-throughput cell based screening 
approach. HeLa cells were exposed in vitro to SM83 
and izTRAIL in addition to a combined library of about 
3000 FDA-approved small molecule inhibitors and 
cell viability assessed (see Materials and Methods). Of 
the 3000 small molecule inhibitors assessed, we found 
that the topoisomerase I inhibitor camptothecin (CPT) 
most profoundly enhanced the cytotoxic effect of SM83 
(Table 1). In addition to the enhancing effect of CPT, 
we also found that different formulations of CPT such 
as 10-hydroxycamptothecin also enhanced the effects of 
SM83, further confirming that CPT can be effectively 
combined with SMs and TRAIL. We then asked whether 
this combination is more cytotoxic in a specific genetic 
background and treated a panel of premalignant and 
cancer cell lines with izTRAIL, SM83 and CPT alone or in 
combination (data not shown). Viability tests showed that 
the immortalized human epithelial (HME) cell line bearing 
a KI G13D mutation in the KRAS gene (D13/+) is far 
more sensitive to SM83 plus CPT treatment compared to 
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Figure 1: oncogenic KRAS increases sensitivity of HMe cells to dnA-damaging agents and trAIl. (A) The parental 
human epithelial (HME) cell line and the isogenic cell lines with knock-in mutations in KRAS (G13D), PI3K (H1047R) and EGFR 
(delE746A750) were treated with varying doses of CPT alone (left panel) or in combination with 100 nM SM83 (right panel). Viabilities 
are shown after 24 h of treatment. (B) HME D13/+ cells were pre-incubated with DMSO, 50 μM z-VAD, 20 μM Nec-1 (left panel), 10 µg/
ml Infliximab (IFX, middle panel) and 10 µg/ml Enbrel (right panel) for 1 h and subsequently treated with 100 nM SM83 and 1 μM CPT. 
Cell viability was determined after 24 h. (C, D) HME +/+ and HME D13/+ cells were mock treated and treated with 100 nM SM83, 1 μM 
CPT and with their combination for 6 h. Cells were lysed and subjected to western blot to detect the apoptosis markers cleaved PARP, 
caspase-3 and caspase-8 (C) and the SM targets cIAP1, cIAP2 and XIAP (D). Actin is the loading control, asterisks show the cleaved forms 
p17/p19 of caspase-3 and the pro-caspase p55/p57 forms of caspase-8, together with its cleaved forms p41/p43. One representative of two 
independent experiments is shown. 
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the parental HME or to HME carrying mutations activating 
PI3K and EGFR (Figure 1A). Moreover, HME D13/+ cells 
were more sensitive to izTRAIL alone or in combination 
with SM83 (Figure S1 upper panels), to the topoisomerase 
II inhibitor etoposide (ETO) and to neocarzinostatin 
(NCS), a DNA double strand break inducer (Figure S1 
lower panel), suggesting a general enhanced sensitivity 
to cell death more than a specific mechanism favoring 
CPT-mediated death. Pre-treatment with pan-caspase 
inhibitor z-VAD strongly supports the idea that SM83/CPT 
treatment kills HME D13/+ cells through an apoptotic 
mechanism (Figure 1B left panel). In fact, the blocking 
of caspases resulted in almost complete protection from 
the treatment, while necroptosis inhibitor Necrostatin-1 
(Nec-1) showed only a negligible effect. Importantly, 
as TNF is known to be a pivotal player in SM-mediated 
cell death, HME D13/+ were also pre-treated with the 
TNF-specific blockers Infliximab (Figure 1B middle 
panel) and Enbrel (Figure 1B right panel) which both 
remarkably rescued cells from the treatment, confirming 
the involvement of TNF in the SM83/CPT cell killing. 
Finally, by biochemical analysis we further confirmed 
that SM83 strongly increases the pro-apoptotic effect of 
CPT, as is evident from the substantial accumulation of 
cleaved PARP, caspase-8 and -3 (Figure 1C). Importantly, 
the altered sensitivity to treatment in cells with wild type 
or mutated KRAS did not stem from a diverse expression 
of the SM known targets cIAP1, cIAP2 and XIAP (Figure 
1D), which are also depleted at the same level by SM83.
endogenous and ectopic oncogenic KRAS 
sensitizes human epithelial cells to sM83 and cPt 
treatment
To further investigate the role of mutated KRAS in 
the increased sensitivity of HME, the cytotoxic response 
to CPT and SM83 was assessed following total KRAS 
knockdown. The results showed that reduced KRAS 
decreased the toxicity by about 50% (Figure 2A), thus 
confirming the involvement of KRAS in the enhanced 
sensitivity. Unfortunately, the lack of an antibody 
specific for mutant KRAS did not allow us to determine 
the efficiency of G13D down-regulation (Figure S2). 
Furthermore, the silencing also affected wild type KRAS, 
which might also have a protective role to the treatment. To 
overcome this limit, KRAS G13D was inducibly expressed 
in HME cells using doxycycline. Augmented levels of 
phosphorylated ERK1/2 (Figure 2B), a down-stream 
effector of KRAS, and GST-RBD pull-down experiments 
confirmed the increased expression of activated KRAS 
(Figure 2C) paralleled by an hypersensitivity to SM83/
CPT co-treatment (Figure 2D). We then repeated the 
experiments with another human epithelial cell line to 
exclude a possible cell line-specificity of our observation. 
MCF10A transduced with the KRAS G13D inducible 
vector confirmed that expression of mutant KRAS 
causes the phosphorylation of ERK1/2 (Figure 2E) and 
hypersensitivity to cell death (Figure 2F).
oncogenic KrAs-mediated up-regulation of noxa 
sensitizes cells to sM83/cPt co-treatment
To determine the mechanisms by which oncogenic 
KRAS sensitizes non-tumoral cells to treatment, several 
cell lines expressing endogenous and ectopic KRAS 
G13D were analyzed by western blot for the levels of 
pro- and anti-apoptotic proteins of the Bcl-2 family (data 
not shown). In accordance to other works, we found that 
the presence of oncogenic KRAS considerably increases 
the basal levels of Noxa in untreated cells. Accordingly, 
HME bearing the KI G13D mutation displayed higher 
levels of Noxa compared to the parental cell line (Figure 
3A left panel), while the basal levels of the Noxa natural 
antagonist Mcl-1 were not affected by oncogenic KRAS 
expression, but markedly dropped after CPT treatment 
in a SM83-independent manner. Moreover, transient 
induction of ectopic KRAS G13D in HME and MCF10A 
parental cell lines concurred to a marked increase of Noxa 
levels in both cell lines (Figure 3A right panels, upper and 
lower panel respectively). In line with these data, KRAS 
silencing reduced the levels of Noxa in HME KRAS G13D 
cells (Figure S2). Furthermore, since Mcl1 levels were 
reduced concurrently to Noxa up-regulation in HME cells 
(Figure 3A left panel), we checked whether Noxa increase 
was responsible for Mcl1 down-regulation. Mcl1 levels 
were therefore detected in KRAS G13D-induced HME 
cells which showed that the sole Noxa up-regulation in not 
sufficient to affect Mcl1 levels in untreated cells. We then 
analyzed by western blot HME KI D13/+ cells silenced 
with control or Noxa-specific siRNAs and treated with 
increasing concentrations of CPT (Figure 3B). Also in this 
case Mcl-1 stability was independent of Noxa presence, 
suggesting that Mcl-1 down-regulation stems from the 
treatment and not from Noxa up-regulation. To determine 
table 1: best hits from the high-throughput screening. 
HeLa cells were treated with FDA-approved drugs in 
combination with SM83 and izTRAIL. The most effective 
10 compounds enhancers of the cytotoxic effect are listed.
compound P-value
10-hydroxycamptothecin 0,000103319
Camptothecin 0,000040974
Camptothecine (S,+) 0,001697753
AMSACRINE 0,000274229
FLUOROURACIL 0,000537959
Aminacrine hydrochloride 0,015471379
Decitabine 0,000022640
MEFLOQUINE 0,000168791
Sutent 0,000444038
NETILMICIN SULFATE 0,005887782
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whether the oncogenic KRAS-dependent accumulation of 
Noxa is responsible for the hypersensitivity to SM83/CPT, 
viability tests were performed after Noxa depletion (Figure 
S2). The results showed that Noxa silencing confers 
resistance to treatment in HME D13/+ cells (Figure 3C).
KrAs-induced up-regulation of noxa is mediated 
by erK2
We next investigated the mechanisms responsible 
for the acquired sensitivity of KRAS-mutated HME to 
treatment. Both parental and D13/+ HME cell lines were 
treated with CPT and SM83 in the presence of various 
inhibitors of the MAPK, AKT and PI3K pathways which 
can be stimulated by activated RAS. In parental cells, 
the administration of MEK1/2 inhibitors PD98059 and 
UO126, AKT inhibitor Triciribine or PI3K inhibitor 
LY294002 did not affect significantly the toxicity of 
SM83/CPT treatment (Figure 4A). In contrast, both 
MEK1/2 inhibitors partially protected D13/+ HME cells 
from SM83/CPT treatment and conferred resistance at the 
same degree as parental cells (Figure 4A). Having found 
that Noxa is a pivotal mediator of KRAS-dependent 
increased sensitivity to the combination (Figure 3C), we 
evaluated whether the MAPK pathway was responsible 
for the increased levels of Noxa. We found that both 
MEK inhibitors reduced, as expected, the levels of 
phosphorylated ERK1 and ERK2, and concurrently 
reduced the levels of Noxa (Figure 4B). Interestingly, 
also Mcl1 levels were slightly reduced by the MEK 
inhibitors, suggesting that both Noxa and Mcl1 expression 
is regulated by the MEK/ERK pathway. Importantly, 
MEK inhibition slightly reduced Noxa basal levels also 
in parental HME (left panel) suggesting that the MAPK 
Figure 2: endogenous and ectopic mutated KRAS confers sensitivity to sM83 and cPt co-treatment. (A) HME +/+ and 
HME D13/+ were transfected with siRNA targeting KRAS for 48 h and subsequently treated with 100 nM SM83 and 1 μM CPT. Cell 
viability was determined after 24 h of treatment. (B) HME pINDUCER20-Mock (Mock) and HME pINDUCER20-KRAS G13D (G13D) 
were incubated with doxycycline (Dox, 250 ng/ml) for 48 h, lysed and a western blot was performed. The presence of activated KRAS was 
determined by detection of phosphorylated ERK1/2. (C) Active GTP-RAS was purified in cells stimulated as in (B) by pull-down assay 
using the recombinant RBD domain of RAF1; HME D13/+ are shown as positive control for activated KRAS. (D) HME Mock and KRAS 
G13D were incubated with Dox (250 ng/ml) for 48 h and treated with 100 nM SM83 and 1 μM CPT. Cell viability was determined after 24 
h. (E) MCF10A Mock and KRAS G13D were incubated with Dox (250 ng/ml) for the indicated time, lysed and analyzed by western blot 
for the detection of ERK1/2 and phosphorylated ERK1/2. Actin is shown as a loading control. (F) MCF10A Mock and KRAS G13D were 
incubated with Dox (250 ng/ml) for 48 h and treated with 100 nM SM83 and 0.1 μM CPT. Cell viability was determined after 24 h. One 
representative of two independent experiments is shown.
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pathway stimulates Noxa also in physiological conditions. 
To understand whether MEK targets ERK1 and ERK2 both 
contribute to Noxa regulation, we silenced each of them 
in D13/+ HME cells and found that only ERK2 down-
regulation reduced Noxa levels, while ERK1 silencing 
marginally increased accumulation of Noxa (Figure 4C 
right panel). Again, Mcl1 was not down-regulated by 
Noxa accumulation, further confirming that the treatment 
with CPT, and not Noxa up-regulation, was responsible for 
Mcl1 reduction in HME cells (Figure 3A). In line with the 
regulation of Noxa observed in figure 4C, ERK1 silencing 
slightly, but significantly, enhanced the sensitivity of 
D13/+ HME cells to SM83/CPT treatment, while ERK2 
silencing resulted in the opposite effect (Figure 4D).
sensitivity to sM83/cPt is independent of KrAs 
status in a panel of colorectal cancer cell lines
Our findings support the notion that oncogenic 
KRAS can sensitize premalignant cells to SM83/CPT 
treatment. We then considered whether this also occurs 
in malignant cells, and for this reason we employed a 
panel of isogenic CRC cell lines where mutated KRAS 
is either KI (+/+ and D13/+, SW48 and Lim1215) or KO 
(D13/- and +/-, HCT-116 and DLD1). Surprisingly and in 
Figure 3: Increased noxa expression in KRAS-mutated HMe favours sM83/cPt-induced cell death. (A, left panel) HME 
+/+ and HME D13/+ cells were treated with 100 nM SM83 and 1 μM CPT for 6 h, lysed and subjected to western blot to detect Noxa and 
Mcl1 levels. (A, right panel) HME/MCF10A Mock and KRAS G13D were incubated with Dox (250 ng/ml) for the indicated time and 
subjected to western blot to detect Noxa and Mcl1 levels. Actin is shown as the loading control. (B) HME D13/+ cells were trasfected with 
control and Noxa-targeting siRNAs and, after 48 h, were treated with the indicated concentration of CPT (µM) for 6 h. Cells were then lysed 
and analyzed by western blot to evaluate Mcl1 levels. Noxa is shown to check the silencing efficiency and actin as the loading control. (C) 
HME +/+ and HME D13/+ were transiently transfected with siRNA targeting Noxa for 48 h and subsequently treated with 100 nM SM83 
and 1 μM CPT. Cell viability was determined after 24 h. One representative of two independent experiments is shown.
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Figure 4: erK2, but not erK1 is responsible for KrAs-dependent noxa-induction. (A) HME +/+ and HME D13/+ cell 
lines were pre-incubated with 50 μM PD98059, 25 µM UO126, 20 μM Triciribine and 20 μM LY294002 for 2 h, and then treated with 100 
nM SM83 and 1 µM CPT. Cell viability was quantified after 24 h. One representative of three independent experiments is shown. (B) HME 
+/+ (left panel) and HME D13/+ (right panel) cell lines were treated with 50 μM PD98059, 25 nM UO126, 20 μM Triciribine and 20 μM 
LY294002 for 2 h, and subsequently analyzed by western blot to detect the phosphorylated forms of AKT, ERK1 and ERK2, their total 
levels (upper panels) or Noxa and Mcl1 (lower panels). Actin is shown as loading control. (C) HME +/+ and HME D13/+ were transiently 
transfected with the indicated siRNAs for 72 hours and subsequently analyzed by western blot to detect total and phosphorylated ERK1 and 
ERK2, and their total levels (left panel), Noxa and Mcl1 (right panel). Actin is shown as loading control. (D) Parental HME +/+ and HME 
D13/+ cells were silenced for 48 h and then treated with DMSO and 100 nM SM83 plus 1 µM CPT for further 24 h. One representative of 
three independent experiments is shown. * P < 0.05 vs siCtr.
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contrast to the premalignant settings, the sensitivity of the 
CRC cell lines to SM83/CPT treatment was independent 
of the KRAS status (Figure 5A-D). We then investigated 
the Noxa status, which was responsible for the increased 
sensitivity of normal epithelial cells bearing oncogenic 
KRAS, and found that its levels were unaffected by the 
presence of mutated KRAS (Figure 5E-H). Likewise, the 
levels of Noxa-antagonist Mcl1 were not repressed by the 
treatment with CPT and/or SM83, and further experiments 
confirmed an increased stability of Mcl1 in colorectal 
cancer compared to HME cells (Figure S3). Noxa basal 
levels were however higher in CRC than in HME cell lines 
(data not shown), suggesting that pro-apoptotic mediators 
can even be up-regulated in tumor cells, but there are 
likely other activated pathways that counterbalance the 
potential pro-apoptotic stimuli.
Aberrant activation of AKt counterbalances 
KrAs-mediated pro-apoptotic scenario in 
colorectal cancer cells
Despite the presence of mutant KRAS, our findings 
suggest that cancer cells are not sensitized to SM83/CPT 
treatment. Therefore, we hypothesized that malignant 
progression might have caused the deregulation of other 
pathways that can counterbalance the potential apoptotic 
effect of oncogenic KRAS. Interestingly, HCT116 and 
DLD1 cells bear mutated PI3K, which results in hyper-
activation of the PI3K/AKT pathway, a signaling cascade 
known to promote cell survival. For this reason, we treated 
HCT116 and DLD1 cells bearing mutated and wild type 
KRAS with SM83/CPT after pre-treatment with inhibitors 
of MEK1/2, AKT and PI3K. Interestingly, and concordant 
to our hypothesis, AKT inhibition restored sensitivity 
to the treatment only in the presence of mutant KRAS 
(Figure 6A and 6B). Noxa levels were lowered by MAPK 
blocking (Figure 6C and 6D) as already observed in HME 
cells (Figure 4B), but were not affected by AKT inhibition, 
suggesting that the AKT pathway blocks the pro-death 
effect triggered by oncogenic KRAS in an independent 
fashion. Importantly, AKT inhibition sensitized to 
SM83/CPT treatment also CRC cell lines bearing wild 
type PI3K (Figure S4), further supporting the idea that 
AKT counteracts the pro-death stimulus deriving from 
oncogenic KRAS. Surprisingly, LY294002 treatment, 
which reduced AKT activation, did not sensitize to SM83/
CPT treatment (Figure 6C and 6D). We speculate that this 
stems from the fact that the LY294002 inhibitor did not 
completely abolish AKT phosphorylation and therefore 
we tested the GDC-0941 PI3K inhibitor. This compound 
reduced the AKT activation more efficiently (Figure 6E 
left panel) and sensitized the HCT116 D13/- in the same 
way as Triciribine (Figure 6E right panel). Finally, we 
investigated the mechanisms by which Noxa levels are 
controlled in HCT116 cells and demonstrated that the 
findings described for HME are true also in this cancer cell 
line. In fact, the targeting of ERK1 by silencing enhanced 
the levels of Noxa, while a specific siRNA targeting ERK2 
slightly reduced its expression (Figure 6F).
dIscussIon
In our work, we searched for FDA-approved drugs 
that increase the cytotoxic activity of IAP-antagonizing 
compounds and death ligands. For this purpose, using a 
high-throughput approach, we combined SM83 [25] and 
izTRAIL [29] to a library of about 3000 compounds. 
CPT was identified several times among the best hits 
and validated, alone or in combination with SM83 and/
or izTRAIL, in a panel of normal and cancer cell lines 
bearing KI and KO mutations in genes frequently mutated 
in cancer. The employment of isogenic cell lines with 
distinct point mutations is a powerful tool to comprehend 
the effect of oncogene activation [31] and addiction [32], 
and synthetic lethal interactions [27, 33] in cancer cells. 
With this approach, we found that the endogenous and 
ectopic expression of KRAS bearing the G13D mutation 
sensitizes normal, but not cancer cells, to CPT plus SM83 
or TRAIL treatment, and to other DNA-damaging agents.
Since oncogenic KRAS stimulates the up-regulation 
of the pro-apoptotic protein Noxa [10, 34], we checked 
the occurrence of this event in premalignant cells and 
whether it was associated with the increased sensitivity 
to treatment. In both human epithelial cells HME and 
MCF10A, the expression of oncogenic KRAS was 
indeed responsible for the up-regulation of Noxa in a 
MEK/ERK-dependent manner and for the augmented 
death upon SM83/CPT treatment. Accordingly, chemical 
inhibition of the MEK1/2 kinases that results in prevention 
of ERK1/2 phosphorylation and silencing of ERK2, but 
not ERK1, down-regulated Noxa in HME D13/+ to levels 
comparable to parental HME (+/+) cells. Of note, ERK2 
silencing slightly, but reproducibly, protected HME D13/+ 
cells, while ERK1 silencing even sensitized to SM83/CPT 
treatment and simultaneously increased Noxa basal levels 
especially in CRC cell lines. The observation that ERK1 
and ERK2 display opposite effects in regulating Noxa 
levels and mediating chemotherapy responsiveness was 
also described in hepatocellular carcinoma cells [35]. In 
this case, ERK2 knockdown was responsible for increased 
Noxa levels after cisplatin treatment. Although we 
investigated Noxa basal levels in our experiments, these 
contrasting results strongly support that ERK1 and ERK2 
mutually regulate each other [36] in a cell type-dependent 
manner. Surprisingly, MEK inhibitors strongly prevented 
treatment cytotoxicity, while siRNA targeting ERK1 
and ERK2 only have a modest effect, despite siERK2 
efficiently down-regulated Noxa levels. This suggests that 
other unknown regulatory mechanisms between the two 
ERK proteins eventually impact on the treatment outcome.
We then asked whether our findings are true not only 
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Figure 5: oncogenic mutation of KRAS does not confer sensitivity to combined sM83/cPt nor stimulates noxa levels. 
SW48 +/+ and SW48 D13/+ (A), HCT116 +/- and HCT116 D13/- (B), Lim1215 +/+ and Lim1215 D13/+ (C), DLD1 D13/- and DLD1 +/- 
(D) cell lines were treated with DMSO and the combination of SM83 and CPT at varying concentrations. Cell viability was evaluated after 
24 h. One representative of three independent experiments is shown. SW48 +/+ and SW48 D13/+ (E), HCT116 +/- and HCT116 D13/- (F), 
Lim1215 +/+ and Lim1215 D13/+ (G), DLD1 D13/- and DLD1 +/- (H) cell lines were treated with DMSO and 100 nM SM83, 0.1 µM 
CPT either alone or in combination for 6 h. Cells were lysed and analyzed by western blotting to determine Noxa and Mcl1 levels. One 
representative of two independent experiments is shown. Asterisk indicates the specific band of Actin shown as loading control.
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Figure 6: Aberrant AKt activation protects Hct116 and dld1 cells from the pro-death effect of oncogenic KRAS. 
(A) HCT116 and (B) DLD1 cells were pre-incubated with 50 μM PD98059, 25 μM UO126, 20 μM Triciribine and 20 μM LY294002 for 
2 h, and then mock-treated or treated with 100 nM SM83 and 1 µM CPT. Cell viability was quantified after 24 h. (C) HCT116 and (D) 
DLD1 cells were treated for 2 h with the indicated inhibitors as in (A) and then analyzed by western blot to detect Noxa levels and total 
and phosphorylated AKT and ERK levels. Actin is shown as loading control. (E, left panel) HCT116 D13/- cells were treated with 1 μM 
GDC-0941 for 2 h and analyzed by western blot to detect total and phosphorylated levels of AKT. Actin is shown as the loading control. 
(Right panel) Viability of HCT116 D13/- pre-treated with 1 μM GDC-0941 for 2 h and then treated with 100 nM SM83 and 1 µM CPT. Cell 
viability was quantified after 24 h and expressed as viability percentage to inhibitor alone. (F) HCT116 cells were transfected with siRNAs 
targeting ERK1 and ERK2, cells were collected after 72 h and analyzed by western blot to detect Noxa and total and phosphorylated levels 
of AKT and ERK. Actin is shown as loading control.
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in premalignant cells, but also in cancer cells. To this end, 
a panel of isogenic colon cancer cell lines with KI and KO 
mutations of KRAS was tested. In clear contrast to HME 
and MCF10A cells, Noxa levels did not depend on KRAS 
status in cancer cells and in line with this observation cell 
sensitivity was almost identical in each pair of isogenic 
cells. Basal levels of Noxa in cancer cells were higher 
than in epithelial cells (data not shown), suggesting that 
tumor cells constitutively express some pro-apoptotic 
proteins at high level, but could also activate parallel 
pro-survival pathways to counteract the pro-death signals 
supported by the MEK/ERK axis. Considerable evidence 
shows that mutations in the RAS/MEK/ERK cascade are 
associated to aberrant activation of PI3K/AKT signaling 
[37] and therefore both pathways should be targeted 
simultaneously for effective responsiveness to treatment 
[11, 38]. In accordance to this hypothesis, HCT116 cells 
and DLD1, which bear PI3K activating mutations, are 
sensitized to SM83/CPT treatment when pre-treated 
with AKT inhibitors only in the presence of oncogenic 
KRAS, supporting the notion that AKT is protecting from 
oncogenic KRAS-dependent cancer cell sensitization 
(Figure 7). It is important to note that this protective role 
was demonstrated also in cells bearing wild type PI3K 
(Figure S4), confirming the general pivotal role of AKT in 
counterbalancing the pro-death effect of oncogenic KRAS.
In conclusion, our work has two main implications. 
First, targeting down-stream effectors of oncogenes might 
result in an immediate and transient anti-proliferative 
effect often achieved by conventional therapies, but, 
more importantly, could also shut-down the pro-death 
signals derived from oncogene activation. Secondly, for 
a successful treatment, targeting of the EGFR/MAPK 
pathway alone is not sufficient [39], as it results in 
emerging protecting mutations [4, 40], feedbacks [41] 
and incomplete responses. It is therefore imperative to 
characterize and inhibit also the aberrantly activated 
survival pathways in a combination treatment, in order 
to overcome the anti-apoptotic effect of PI3K/AKT 
activation and simultaneously to exploit the pro-death 
signal stemming from oncogenic activation.
Figure 7: Proposed mechanism for oncogenic KrAs-mediated sensitization to cell death. In premalignant models, normal 
epithelial cells expressing endogenous or ectopic mutated KRAS express high levels of Noxa due to the hyper-activation of MAPK kinases 
and in particular of ERK2. In these settings, the basal activation of the PI3K/AKT pathway is not sufficient to protect from this pro-death 
stimulus and treatment with several cytotoxic agents results in Noxa-dependent cell killing. In contrast, in CRC cells, Noxa levels are 
independent of KRAS status and oncogenic KRAS-bearing cells respond to treatment to the same extent as in the presence of wild-type 
KRAS. In fact, mutated PI3K and up-stream stimuli likely deriving from the tyrosine kinase receptors activate AKT, which counterbalances 
the potential pro-death stimulus deriving from oncogenic KRAS.
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MetHods
cell lines
The human isogenic hTERT-immortalized mammary 
epithelial cell lines HME +/+ and HME D13/+, and the 
human epithelial mammary MCF10A together with the 
isogenic pairs of colorectal cancer cell lines SW48 +/+ and 
SW48 D13/+, HCT116 +/- and HCT116 D13/-, Lim1215 
+/+ and Lim1215 D13/+, DLD1 D13/- and DLD1 +/- have 
already been described [4, 27]. HME isogenic pairs and 
MCF10A cell lines were cultured in DMEM-F12 (Gibco), 
supplemented with 10% FBS (LONZA), 2 mM glutamine 
(LONZA), 20 ng/ml EGF (Immunological Science), 10 
µg/ml insulin (Sigma), 500 µg/ml hydrocortisone (Sigma-
Aldrich). SW48 and DLD1 isogenic pairs were cultured 
with DMEM (Gibco) supplemented with 10% FBS and 
2 mM glutamine. Lim1215 isogenic pairs were cultured 
with RPMI (LONZA) supplemented with 10% FBS, 
2 mM glutamine and 1 µg/ml insulin. HCT116 were 
cultured in RPMI, supplemented with 2 mM glutamine, 
sodium pyruvate (LONZA), and non-essential amino acids 
(LONZA). HeLa cells for the high-throughput screening 
and packaging HEK293FT (Life Technologies) for 
lentiviral production were cultured in DMEM with 10% 
FBS. All cell lines were mycoplasma-free as determined 
by Takara Mycoplasma Detection Kit (Clontech).
reagents
Antibodies targeting pan-RAS, Noxa (CalBiochem), 
Actin and ERK1/2 (Sigma), cleaved-PARP, cleaved 
caspase-3, phosphoERK1/2 (Thr202/Tyr204), pAKT and 
AKT (Cell Signaling), cIAP1 (R&D Systems), cIAP2 and 
XIAP (BD Biosciences), caspase-8 (Enzo Life Sciences) 
and Mcl-1 (Santa Cruz Biotechnology) were employed 
in western blot experiments. z-VAD(OMe)-FMK was 
purchased by BIOMOL, Necrostatin-1 from Enzo Life 
Sciences. PD98059 and UO126 were purchased from 
CalBiochem, LY294002 from Sigma, GDC-0941 and 
Triciribine from Selleckem. Infliximab (Schering-Plough) 
and Enbrel (Wyeth Pharmaceuticals) were used as TNF 
blockers. CPT and neocarzinostatin were purchased from 
Sigma-Aldrich, etoposide by Teva. SM83 synthesis has 
been described elsewhere [25, 28], while izTRAIL was 
purified as already shown [29]. Mutant KRAS (G13D) 
was cloned in the pINDUCER20 and lentiviral particles 
prepared modifying an already described protocol [30] 
and using Lipofectamine 2000 as transfection reagent. 
Expression of the transgene was induced by doxycycline 
(Sigma-Aldrich) at the indicated concentrations.
High-throughput screening
On day 1, 350 HeLa cells/well were seeded in 
384-well white plates in 20 µl medium. At day 2, media 
was changed with cells being exposed to 100 nM SM83 
in addition to FDA-approved drug libraries (ENZO 
Life Sciences, MicroSource Discovery Systems Inc. 
and Prestwick Chemical, France) with the drug library 
compounds present at a final concentration of 1 µM. At 
day 3, cells exposed to SM83 were also exposed to 20 
pg/ml izTRAIL. Cell viability was estimated on day 5 by 
CellTiter-Glo (Promega). Hits were selected due to their 
capability to enhance the cytotoxic activity of SM83/
izTRAIL and then validated using the same HeLa cells 
employed in the screening. In validation experiments, 
SM83 and izTRAIL were administered alone and in 
combination, also changing the schedule and pre-treating 
cells with SM83 24 h before izTRAIL or administrating 
these compounds simultaneously. On the basis of 
these results, validated hits were tested in a panel of 
premalignant and cancer cell lines.
Western blot
Cells were harvested by centrifugation at 4500 
rpm for 5 min at 4°C. After washing once with PBS, 
lysates were prepared by resuspending cell pellets in 
60-100 µl lysis buffer (125 mM Tris HCl pH 6.8, 5 % 
SDS) supplemented with 1x complete protease (Roche 
Diagnostics) and phosphatase inhibitors (Sigma-Aldrich). 
Lysates were boiled at 99°C, sonicated for 20 seconds at 
RT. Then lysates were centrifuged at 13000 rpm for 20 
min at RT and cleared supernatants were transferred into 
a new tube and frozen at -20°C. Cell lysates were mixed 
with 4x reducing SDS-Sample buffer containing 10% 
β-mercaptoethanol (Sigma-Aldrich) and heated for 10 
min at 99°C. Proteins (50 µg) were separated by SDS-
PAGE using pre-cast 4-12% BisTris NuPAGE gels (Life 
Technologies), blotted to PVDF membranes (Millipore), 
which were washed with PBS-tween for 5 min, blocking 
buffer made of 4% non-fat milk in PBS-tween for 30 min 
and then incubated overnight with the indicated primary 
antibodies. Proteins were detected after hybridization 
with appropriate horseradish peroxidase (hrp)-conjugated 
secondary antibodies by adding a chemiluminescent 
substrate (EuroClone). 
cell viability assays
96-well optical bottom, polymer base white plates 
(Thermo Scientific) were used for viability tests. At day 
1, 10000 cells per well were seeded in 100 µl medium. 
At day 2, cells were treated adding the indicated drug(s) 
in 10 µl volume per well. At day 3, cell viability was 
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determined using the CellTiter-Glo assay according to 
the manufacturer’s instructions. Statistical analysis was 
performed with GraphPad Prism 5.02 using the two-tailed 
unpaired t-test.
transfection and lentiviral transduction
To achieve transient knock-down of target proteins 
in HME cells, a reverse transfection protocol employing 
siRNAs (Qiagen) and RNAiMAX (Life technologies) was 
used. Briefly, 3.25 µl RNAiMAX and 200 µl Optimem 
(GIBCO) were mixed and incubated for 5 min at RT. 
Subsequently, 3.25 µl siRNA of a 20 µM stock were 
added, mixed and incubated for further 30 min at RT. The 
transfection mix was placed in a 6-well plate and 0.15 x 
106 cells seeded in 800 µl on top. 
Tumor cells were seeded the day before transfection 
and the same transfection mix as for reverse transfection 
was added on top of cells 24 h later. The cells were then 
incubated for 48 h before being drug-treated for further 24 
h or cultured for 72 h before stopping the experiment. In 
each experiment, scramble siRNAs (siCtr) were used as 
a control.
Cells transduced with lentiviral particles 
were cultured in the presence of medium collected 
from HEK293FT packaging cells transfected with 
pINDUCER20-KRAS G13D (referred to as G13D) or 
empty vector (Mock). After 48 h, medium was replaced 
and fresh medium added in the presence of 500 µg/ml 
G418 (Life Technologies).
ras-GtP pull-down assay
2.5 x 106 cells were seeded into 10 cm dishes. The 
next day, cells were incubated with and without 250 
ng/ml of Dox. Cell lysis and RAS-GTP pulldown was 
performed. Cells were lysed in 500 μl of IP-lysis buffer 
supplemented with a cocktail of protease inhibitors. To 
fully detach lysed cells, they were scratched using a cell 
scraper and transferred into tubes for a 30-minute lysis 
at 4 °C on a rotator. Lysates were centrifuged at 13000 
rpm for 30 min and cleared supernatants were transferred 
to a new tube. RAS-GTP was precipitated using beads 
coated with the RAF1-binding domain RBD recombinant 
protein. The following day, beads were washed 5 times 
with IP-lysis buffer and precipitated protein complexes 
were eluted from the beads via boiling in SDS-Sample 
buffer for 10 minutes at 80°C. Proteins were separated by 
SDS-PAGE and analyzed by western blot. As a loading 
control, proteins were stained by blue coomassie (Thermo 
Scientific Pierce). 
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